Clinical Trials Browser

Recurrence × Ipilimumab × Dermatologic × Clear all

NCT02668770 2026-04-07

Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies

Phase 1 Terminated

Melanoma, Neoplasm Metastasis, Recurrence

NCT03993379 2025-12-26

PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors

Phase 2 Terminated

3 enrolled 7 charts

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma, Neoplasms, Recurrence